1454656-85-9

Upstream product

• 98-16-8 3-trifluoromethylaniline 
• 1454656-81-5 4-(2-methylsulfanyl-5,7-dihydro-pyrrolo[3,4-d]pyrimidin-6-yl)-pyridine-2-carboxylic acid (3-trifluoromethyl-phenyl)-amide 
• 916059-20-6 2-(methylthio)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine 
• 365996-86-7 tert-Butyl 2-(methylsulfanyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxylate 
• 157327-42-9 3-(dimethylaminomethylene)-4-oxo-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1454657-40-9 4-bromo-N-[3-(trifluoromethyl)phenyl]pyridine-2-carboxamide 
• 30766-03-1 4-bromo-2-picolinic acid 

Relevant academic research and scientific papers

KINASE INHIBITORS

The present invention relates to compounds of formulae I and II wherein the variables are as defined herein. These compounds are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

METHOD OF TREATING CONDITIIONS WITH KINASE INHIBITORS

The present invention relates to a method of treating ophthalmic diseases and conditions, e.g. diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, etc., in a subject comprising administering to said subject a therapeutically effective amount of at least one compound of formula I or a prodrug, pharmaceutically acceptable salt, racemic mixtures or enantiomers of said compound. The compounds of formula I are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.